Wegovy Tablets for Weight Loss

Yes. LIVVE's weight-management pathway is available to eligible adults of all genders. Suitability is based on clinical criteria, medical history, current medicines and individual treatment goals.

Wegovy tablets may be considered for adults with a BMI of 30 or above, or a BMI between 27 and 30 alongside at least one weight-related health condition. Eligibility is confirmed through an individual clinical assessment and is not based on BMI alone.

Take one tablet once daily on an empty stomach after fasting for at least 8 hours. Swallow it whole with a small amount of water, up to 120 mL, then wait at least 30 minutes before eating, drinking or taking any other oral medicine.

No. Swallow the tablet whole. Splitting, crushing or chewing it may affect how the medicine is absorbed.

Food, drinks and other tablets can reduce the absorption of oral semaglutide. Waiting at least 30 minutes after taking Wegovy helps the medicine to be absorbed as intended.

The usual starting dose is 1.5 mg once daily. After at least one month, the dose may increase to 4 mg, then 9 mg and finally 25 mg. Your clinician may keep you at a previous dose for longer if needed.

No. One month is the minimum time at each dose level. Your clinician will consider side effects, appetite, nutrition, weight progress and your overall health before approving an increase.

Skip the missed dose and take your next dose the following day at the usual time. Do not take two tablets on the same day to make up for a missed dose.

No. Wegovy tablets should always be taken as one tablet once daily. Do not combine lower-strength tablets to achieve a higher dose unless your prescriber has given specific instructions.

Contact LIVVE, NHS 111 or another appropriate healthcare professional promptly. Taking too much may increase nausea, vomiting, diarrhoea and dehydration. Seek urgent help if symptoms are severe.

Patients established on Wegovy 2.4 mg injections once weekly may be able to switch directly to Wegovy 25 mg tablets once daily. The tablet is generally started one week after the final injection. People using another injection dose, including 7.2 mg, or who have had a treatment break, need an individual switching plan.

They contain the same active ingredient, semaglutide, but they are taken differently and the milligram strengths are not directly interchangeable. The tablet also contains an ingredient that helps semaglutide pass through the stomach lining, and its absorption is more variable than with an injection. Switching must therefore be clinically supervised.

No. Wegovy tablets should not be used alongside another GLP-1 medicine such as Wegovy injections, Ozempic, Rybelsus or Mounjaro unless a clinician is managing a planned switch.

Possibly, but your diabetes medicines and glucose control need careful review. Wegovy is not a substitute for insulin. Insulin or sulphonylurea doses may need adjustment, and diabetic eye disease may require closer monitoring. Seek urgent advice for sudden or rapidly worsening changes in vision.

Semaglutide is not expected to directly reduce the effectiveness of the contraceptive pill. However, vomiting or severe diarrhoea can affect absorption. Follow the sickness instructions supplied with your contraceptive and seek advice if symptoms continue.

No. Wegovy should not be used during pregnancy or breastfeeding. Tell LIVVE promptly if you become pregnant, think you may be pregnant or are breastfeeding.

Wegovy should be stopped at least two months before a planned pregnancy because semaglutide remains in the body for some time. Speak to your clinician before stopping.

Often, yes, but your full medication list and medical history still need review. Because Wegovy must be taken separately from other oral medicines, your clinician or pharmacist can help you plan the timing of HRT tablets and any other medicines.

Tell your clinician before starting Wegovy tablets. Thyroid monitoring may be considered with levothyroxine, while people taking warfarin or similar medicines may need closer INR monitoring when treatment begins.

Yes. Wegovy can delay stomach emptying. Tell your surgical, endoscopy or anaesthetic team that you take semaglutide and follow their instructions. Do not stop treatment automatically unless advised.

The most common effects are nausea, vomiting, diarrhoea, constipation and indigestion. They are often most noticeable during dose escalation and may improve as your body adjusts.

Seek urgent medical advice for severe and persistent abdominal pain, repeated vomiting, signs of serious dehydration, a severe allergic reaction, sudden or partial loss of vision, or severe constipation with stomach pain, bloating, vomiting or inability to pass wind or stool.

Alcohol is not automatically prohibited, but it may worsen nausea, indigestion and dehydration. It can also affect blood glucose. Consider limiting alcohol when starting treatment or increasing your dose.

Your clinician will discuss maintenance, nutrition, activity, relapse prevention and whether continuing, adjusting or stopping treatment is appropriate. Do not change or stop treatment without advice.

There is no single treatment length for everyone. Treatment may continue while it remains safe, tolerable and beneficial, with regular clinical review.

LIVVE tablet pricing is to be confirmed. Your assessment will confirm whether tablets are suitable for you and which dose pathway is appropriate.

No. Wegovy tablets and Rybelsus both contain semaglutide, but they are separate medicines with different licensed uses and dose schedules. Wegovy tablets are licensed for weight management, while Rybelsus is licensed for type 2 diabetes. Do not switch between them or use them together unless instructed by a prescriber.

Results vary between individuals. In a clinical trial, people taking Wegovy 25 mg tablets as prescribed alongside a reduced-calorie diet and increased physical activity lost an average of 16.6% of their starting body weight over 64 weeks. Some people lost more and others less. Your results will depend on factors such as your health, treatment response, adherence, nutrition and activity.

Some people notice reduced hunger or cravings during the first few days or weeks, but weight-loss progress usually develops gradually. The first three doses are used to help your body adjust, and the full treatment effect is generally expected once you reach the 25 mg maintenance dose. Do not increase your dose early if you have not noticed an immediate change.

Keep Wegovy tablets in their original closed container and protect them from moisture. Do not transfer them into a pill organiser unless a pharmacist confirms that this is appropriate. Keep the medicine out of the sight and reach of children and follow the storage instructions on the UK pack and patient information leaflet.

Wegovy tablets are intended to be taken in the morning after an overnight fast. Take the tablet with plain water and then wait at least 30 minutes before eating, drinking or taking other oral medicines. Speak to LIVVE rather than moving the dose to another time of day yourself.

There is no single best option for everyone. Wegovy tablets may suit someone who wants to avoid injections and can reliably follow the morning fasting routine. Wegovy injections may suit someone who prefers once-weekly dosing and wants to avoid daily tablet absorption rules. Your LIVVE clinician will consider your medical history, current medicines, side effects, treatment response, daily routine and preference before recommending a route. Do not switch between tablets and injections without clinical advice.

Both forms contain semaglutide, but they have not been compared directly in a head-to-head clinical trial. Separate studies suggest that both can support meaningful weight loss when used as prescribed, although results vary and the highest injection doses have produced greater average losses in their respective trials. Your decision should also consider the daily fasting routine, injections, side effects, medical suitability and personal preference.

No. Wegovy 7.2 mg is an injection maintenance option, not a tablet strength. The tablet pathway remains 1.5 mg, 4 mg, 9 mg and 25 mg once daily. If you are using 7.2 mg injections and want to discuss tablets, LIVVE would need to review your treatment history, response, side effects and suitability before advising on any switch.